Acadia Pharmaceuticals Sells Rare Pediatric Disease Review Voucher for $150 Million

Acadia Pharmaceuticals has shared that it will be selling its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million under a newly signed agreement. The PRV was awarded to Acadia in March 2023 after the FDA approved DAYBUE™ (trofinetide) as a treatment for Rett syndrome. Originally licensed from Neuren Pharmaceuticals Limited in 2018, DAYBUE’s licensing agreement includes a stipulation that Neuren will receive one-third of the net proceeds from this sale.

The funds from the PRV sale are set to bolster Acadia’s operations, helping to advance its commercial efforts, research and development projects in CNS and rare diseases, and explore new business opportunities. The transaction remains pending, with standard conditions still to be met, including compliance with the Hart-Scott-Rodino Antitrust Act. Jefferies LLC provided financial guidance to Acadia throughout this process.